HOME >> MEDICINE >> NEWS
First clinical data presented on latest technological advance in haemophilia a therapy

Seville, Spain, May 21, 2002 The first recombinant Factor VIII therapy for Haemophilia A prepared entirely without the use of human- or animal-derived additives was found to be bioequivalent to the current gold-standard recombinant therapy according to data presented today at the XXV International Congress of the World Federation of Hemophilia.

Baxters recombinant antihaemophilic Factor VIII protein-free method (rAHF/PFM), an investigational therapy currently in phase III clinical trials, is a new category of recombinant Factor VIII prepared entirely without the addition of any human or animal raw materials in the cell culture process, purification or final formulation.

Results from a randomized double-blind, cross-over study comparing rAHF/PFM and the control, Recombinate (recombinant antihaemophilic factor), indicate that rAHF/PFM and Recombinate rAHF are bioequivalent and should exhibit comparable hemostatic efficacy in the management of Haemophilia A.

FURTHER REDUCING THEORETICAL RISK
rAHF/PFM is being developed in response to concerns about the theoretical transmission of currently unknown viruses or diseases through the continued use of human- or animal-derived components during the production process and final formulation.

All currently available recombinant Factor VIII therapies use human or animal-derived proteins at some point in their production processes or final product formulations. To date, more than 5 billion units of Recombinate rAHF have been supplied to the haemophilia community since the first clinical study infusion was administered in 1987, and there have been no confirmed cases of disease transmission associated with its use.

However, according to a recommendation from the Medical Advisory and Scientific Council (MASAC) of the National Hemophilia Federation, "all efforts should be made to remove human albumin from recombinant Factor VIII products. Moreover, increased efforts should be made to eli
'"/>

Contact: Deborah Spak
847-948-2349
Porter Novelli
21-May-2002


Page: 1 2

Related medicine news :

1. First head-to-head study to compare lidoderm patch and Celebrex in treating pain
2. First UK cases of previously rare disease reported in gay men
3. First mouse model for multiple system atrophy points to new treatment targets for brain diseases
4. Mayo Clinic researchers create obedient virus; First step to use measles virus against cancer
5. First US kidney cancer vaccine trial underway at Columbia
6. First new treatment for alcoholism in ten years, now available Campral(R) (acamprosate calcium)
7. First blood test to diagnose paralyzing, blinding disease
8. First US SARS vaccine trial opens at NIH
9. First-ever safety study of medical cannabis use in Canada launched
10. First solid evidence that the study of music promotes intellectual development
11. First medical test on CD gets good results

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/16/2019)... ... June 14, 2019 , ... ... Security solutions, today announced it has received the coveted “2019 Best DLP Solution ... that Works Platform along with the latest additions to its Data Security Portfolio ...
(Date:6/14/2019)... , ... June 14, 2019 , ... ... Tempur-Pedic® Mattress & Pink Bag Event® scheduled for Saturday, July 13th. UBCF is ... men and children directly impacted by breast cancer. This second event was added ...
(Date:6/13/2019)... ... June 13, 2019 , ... MMJ BioPharma Cultivation, a premier ... memorandum of understanding (MOU) with MMJ International Holdings to grow cannabis and supply ... BioPharma Cultivation will be supplying MMJIH with extracts from the marijuana plant to ...
(Date:6/13/2019)... ... June 13, 2019 , ... Pure Ratios, the ... cannabis delivery company, Driven Deliveries, Inc., the only publicly traded cannabis delivery service ... the population of California with overnight cannabis delivery to major thriving markets such ...
(Date:6/13/2019)... ... June 13, 2019 , ... ... everyone in healthcare, today announced that Jon Elwell, the company’s CEO, has been ... DirectTrust is a non-profit health care industry alliance created to support ...
Breaking Medicine News(10 mins):
(Date:6/13/2019)... ... June 13, 2019 , ... Homecare Homebase ... the new Smart Scheduling product, part of the HCHB Intelligence Suite, at the ... uses complex algorithms to create highly efficient routing, mapping and scheduling for home ...
(Date:6/13/2019)... ... 13, 2019 , ... Access Healthcare , a leading provider of healthcare ... at the HFMA Annual Conference 2019 which will be held on June ... Access Healthcare, says, “HFMA Annual Conference has inspired us in many ways – right ...
(Date:6/13/2019)... ... , ... RxNT announced today that it has been named by ... RxNT is a leader in healthcare technology solutions. This is the fourth time RxNT ... highlight the best software products from North American small businesses. RxNT won the FrontRunner ...
Breaking Medicine Technology:
Cached News: